Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

23.30 +0.51 (+2.24%)

Streaming Delayed Price Updated: 3:01 PM EDT, Jun 10, 2026 Add to My Watchlist

Price and Volume

Volume	761,019
Open	22.65
Bid (Size)	23.29 (200)
Ask (Size)	23.31 (200)
Prev. Close	22.79
Today's Range	22.56 - 24.00
52wk Range	12.72 - 31.77
Shares Outstanding	50,241,789
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status ↗

June 09, 2026

Arcutis Biotherapeutics (NASDAQ:ARQT) executives said ZORYVE continues to post strong growth and outlined several regulatory and clinical catalysts expected over the next year, while emphasizing that...

Via MarketBeat

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗

June 03, 2026

This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.

Via The Motley Fool

Performance

YTD	-19.7%	-19.7%
1 Month	+9.7%	+9.7%
3 Month	-5.2%	-5.2%
6 Month	-21.7%	-21.7%
1 Year	+64.0%	+64.0%

More News

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

June 03, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Biotherapeutics (NASDAQ:ARQT) Beats Q1 Revenue Estimates but Posts Wider-Than-Expected Loss; Shares Slide ↗

May 06, 2026

Via Chartmill

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Surpasses Q4 Estimates and Raises 2026 Sales Outlook ↗

February 25, 2026

Via Chartmill

Arcutis (ARQT) Q1 2026 Earnings Transcript ↗

May 07, 2026

Via The Motley Fool

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

May 06, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months

April 27, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows Technical Breakout Setup ↗

February 13, 2026

Via Chartmill

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows High-Growth Momentum and Strong Technical Setup ↗

February 11, 2026

Via Chartmill

Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

April 22, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate ↗

April 14, 2026

Via Chartmill

Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know ↗

April 08, 2026

Via The Motley Fool

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

April 07, 2026

From Palvella Therapeutics Inc.

Via GlobeNewswire

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

March 28, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting

March 18, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology

March 10, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth

March 05, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis

March 03, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis (ARQT) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Via The Motley Fool

Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 25, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments

February 24, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit ↗

February 06, 2026

Via The Motley Fool

Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis

February 02, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa

January 26, 2026

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Arcutis Biotherapeutics, Inc. - Common stock publicly traded?

Yes, Arcutis Biotherapeutics, Inc. - Common stock is publicly traded.

What exchange does Arcutis Biotherapeutics, Inc. - Common stock trade on?

Arcutis Biotherapeutics, Inc. - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock?

The ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock is ARQT on the Nasdaq Stock Market

What is the current price of Arcutis Biotherapeutics, Inc. - Common stock?

The current price of Arcutis Biotherapeutics, Inc. - Common stock is 23.30

When was Arcutis Biotherapeutics, Inc. - Common stock last traded?

The last trade of Arcutis Biotherapeutics, Inc. - Common stock was at 06/10/26 03:01 PM ET

What is the market capitalization of Arcutis Biotherapeutics, Inc. - Common stock?

The market capitalization of Arcutis Biotherapeutics, Inc. - Common stock is 1.17B

How many shares of Arcutis Biotherapeutics, Inc. - Common stock are outstanding?

Arcutis Biotherapeutics, Inc. - Common stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.